I
9.18
-0.12 (-1.29%)
| Previous Close | 9.30 |
| Open | 9.30 |
| Volume | 309,832 |
| Avg. Volume (3M) | 360,286 |
| Market Cap | 203,543,552 |
| Price / Sales | 10.81 |
| Price / Book | 5.42 |
| 52 Weeks Range | |
| Earnings Date | 26 Mar 2025 - 31 Mar 2025 |
| Operating Margin (TTM) | -304,535.72% |
| Diluted EPS (TTM) | -2.11 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 1.20% |
| Current Ratio (MRQ) | 3.14 |
| Operating Cash Flow (TTM) | -33.36 M |
| Levered Free Cash Flow (TTM) | -18.45 M |
| Return on Assets (TTM) | -55.19% |
| Return on Equity (TTM) | -119.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | INmune Bio Inc. | Bullish | Bullish |
AIStockmoo Score
1.9
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.88 |
|
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 27.78% |
| % Held by Institutions | 27.69% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Maxim Group, 226.80%) | Buy |
| Median | 26.50 (188.67%) | |
| Low | 23.00 (Scotiabank, 150.55%) | Buy |
| Average | 26.50 (188.67%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 8.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Maxim Group | 13 Feb 2025 | 30.00 (226.80%) | Buy | 9.30 |
| Scotiabank | 11 Feb 2025 | 23.00 (150.54%) | Buy | 8.25 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Apr 2025 | Announcement | INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study |
| 27 Mar 2025 | Announcement | INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update |
| 24 Mar 2025 | Announcement | INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025 |
| 12 Feb 2025 | Announcement | INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer |
| 10 Feb 2025 | Announcement | INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) |
| 28 Jan 2025 | Announcement | INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |